Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 14, 2025 -- Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without type 2 diabetes, according to a study published online Jan. 31 in JAMA Network Open.
Patricia J. Rodriguez, Ph.D., M.P.H., from Truveta Inc. in Bellevue, Washington, and colleagues conducted a retrospective cohort study involving 125,474 adults with overweight or obesity who newly initiated treatment with a dual-labeled GLP-1 receptor agonist (liraglutide, semaglutide, or tirzepatide) between Jan. 1, 2018, and Dec. 31, 2023. Patients were followed for up to two years to assess discontinuation and for two additional years to examine reinitiation.
The researchers found that compared with those with type 2 diabetes, patients without type 2 diabetes had a significantly higher one-year discontinuation rate (64.8 versus 46.5 percent). Significant associations were seen for higher weight loss and higher income with lower rates of discontinuation; a higher risk for discontinuation was seen in association with moderate or severe incident gastrointestinal adverse events (hazard ratios, 1.38 and 1.19 for those with and without type 2 diabetes, respectively). Of 41,792 patients who discontinued and had a discontinuation weight measurement available, one-year reinitiation was lower for those without versus with type 2 diabetes (36.3 versus 47.3 percent). Increased hazards of reinitiation were seen in association with weight regain of 1 percent from discontinuation (2.3 and 2.8 percent for those with and without type 2 diabetes, respectively).
"Greater weight loss and higher income (type 2 diabetes only) were associated with lower discontinuation, while weight regain since discontinuation was associated with higher reinitiation," the authors write.
Several authors disclosed ties to the health care industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
Adverse Pregnancy Outcomes Partly Mediate Association Between Prepregnancy Obesity, CVD Risk
MONDAY, April 21, 2025 -- Adverse pregnancy outcomes (APOs) mediate a small proportion of the association between prepregnancy obesity and cardiovascular disease (CVD) risk in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.